 |
|
|
| |
Antiviral Characterization of a Next Generation Chemical
Series ofHBV Capsid Inhibitors In Vitro and In Vivo
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
Nagraj Mani1, Andrew G. Cole1, Janet R. Phelps1, Cory Abbott1, Andrzej Ardzinski1, Jeff Bechard1, Robbin Burns1, Tim Chiu1, Andrea Cuconati1, Bruce D. Dorsey1, Ellen Evangelista1, Kristi Fan1, Laurel Fu1, Fang Guo1, Haitao Guo2, Troy O. Harasym1, Agnes Jarosz1, Salam Kadhim1, Steven G. Kultgen1,
Kaylyn Kwak1, Amy C.H. Lee1, Alice H. Li1, Sara Majeski1, Kevin McClintock1, Angela Miller1, Chris Pasetka1, Stephen P. Reid1, Rene Rijnbrand1, Alexander Shapiro1, Holly M. Steuer1, Kim Stever1, Sunny Tang1, Xiaowei Teng1, Xiaohe Wang1, Hu Zhang2, Michael J. Sofia1
1Arbutus Biopharma, Burnaby, BC, Canada and Warminster, PA, United States; 2. Indiana University, Indianapolis, IN, United States.
|
| |
|
|
|
|
|
